Brawn Biotech Ltd
Fundamental Score
Brawn Biotech Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of BRAWN across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (120.59%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (48.18%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Balanced Promoter Holding (53.66%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
8 factors identified
Below-Average Return on Equity (-41.33%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-42.52%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (-6.41%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Limited Growth History (-22.97% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Limited Institutional Interest (FII+DII: 0.35%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Brawn Biotech Ltd
About BRAWN
Business Overview
Brawn Biotech Limited engages in the trading of pharmaceutical products in India. It provides pharmaceutical formulations, including antibacterial, cardiovascular, antidiabetic, analgesic, gastrointestinal, antifungal, skin care, antipsychotic, antiasthmatic, antacid, antimalarial, and nutritional products. The company was formerly known as Brawn Pharmaceuticals Limited and changed its name to Brawn Biotech Limited in November 2010. The company was incorporated in 1985 and is based in New Delhi, India.
Company Details
Key Leadership
Corporate Events
Latest News
BRAWN Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Brawn Biotech Ltd (BRAWN)?
As of 09 Feb 2026, 12:22 pm IST, Brawn Biotech Ltd (BRAWN) is currently trading at ₹19.43. The stock has a market capitalization of ₹5.78 (Cr).
Is BRAWN share price Overvalued or Undervalued?
BRAWN is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.
What factors affect the Brawn Biotech Ltd share price?
Key factors influencing BRAWN's price include its quarterly earnings growth (Sales Growth: 48.18%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Brawn Biotech Ltd a good stock for long-term investment?
Brawn Biotech Ltd shows a 5-year Profit Growth of N/A% and an ROE of -41.33%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Brawn Biotech Ltd compare with its industry peers?
Brawn Biotech Ltd competes with major peers in the Pharmaceuticals. Investors should compare BRAWN's P/E of 0.00x and ROE of -41.33% against the industry averages to determine its competitive standing.
What is the P/E ratio of BRAWN and what does it mean?
BRAWN has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.
How is BRAWN performing according to Bull Run's analysis?
BRAWN has a Bull Run fundamental score of 28/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does BRAWN belong to?
BRAWN operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Brawn Biotech Ltd.
What is Return on Equity (ROE) and why is it important for BRAWN?
BRAWN has an ROE of -41.33%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Brawn Biotech Ltd generates profits from shareholders' equity.
How is BRAWN's debt-to-equity ratio and what does it indicate?
BRAWN has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is BRAWN's dividend yield and is it a good dividend stock?
BRAWN offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has BRAWN grown over the past 5 years?
BRAWN has achieved 5-year growth rates of: Sales Growth -22.97%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in BRAWN and why does it matter?
Promoters hold 53.66% of BRAWN shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is BRAWN's market capitalization category?
BRAWN has a market capitalization of ₹6 crores, placing it in the Small-cap category.
How volatile is BRAWN stock?
BRAWN has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for BRAWN?
BRAWN has a 52-week high of ₹N/A and low of ₹N/A.
What is BRAWN's operating profit margin trend?
BRAWN has a 5-year average Operating Profit Margin (OPM) of -6.41%, indicating the company's operational efficiency.
How is BRAWN's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 48.18% and YoY Profit Growth of 120.59%.
What is the institutional holding pattern in BRAWN?
BRAWN has FII holding of 0.00% and DII holding of 0.35%. Significant institutional holding often suggests professional confidence in the stock.